Purchase this article with an account.
Su Chan Lee; Clinical outcomes of selective laser trabeculoplasty in Korean eyes with uncontrolled pseudoexfoliation glaucoma. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4975.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
In an East Asian population, there have been a few studies reporting the clinical results of selective laser trabeculoplasty (SLT) on uncontrolled pseudoexfoliation glaucoma (PXFG). We performed a retrospective, observational study to investigate the efficacy and safety of SLT in Korean eyes with PXFG refractory to maximum tolerated medical therapy.
Twenty-four eyes of 24 patients with medically uncontrolled PXFG were treated with SLT. Intraocular pressure (IOP) was measured before SLT and 1 day, 1 week, 1, 3, 6 months and 1 year after SLT. Treatment success was defined as IOP reduction ≥ 20% without additional laser or glaucoma surgery.
The mean IOP was 27.7 ± 6.5 mmHg and the mean number of anti-glaucoma drug was 3.7 ± 1.0 preoperatively. There was significant IOP decrease at postoperative 1 day (20.9 ± 9.5 mmHg), 1 week (16.0 ± 4.5 mmHg), 1 month (17.7 ± 5.9 mmHg), 3 months (16.0 ± 3.9 mmHg), 6 months (16.8 ± 4.0 mmHg), 1 year (19.5 ± 8.2 mmHg) (all P < 0.05). No significant change was observed in the mean number of anti-glaucoma drug (P > 0.05). The cumulative probability of treatment success at 6 months after SLT was 58% and at 1year after SLT was 50%. More than half (53.8%) of failure was observed within 3 months after SLT. Overall follow up period, there was no significant adverse events except 3 eyes (12.5%) of IOP spike (IOP rise of ≥ 5 mmHg than pretreatment IOP within 1 hour).
SLT seems to be a safe and effective procedure to lower IOP in Korean patients with medically refractory PXFG.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only